Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on December 21, 2015, covering events occurring on December 17 and 18, 2015. The filing details corporate governance changes, including the election of a new director, amendments to bylaws, executive compensation adjustments, and changes in senior management.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on governance and compensation events.
Material Changes and Executive Actions
- Director Election: The Board elected Ken Bate as a director effective December 17, 2015, increasing the Board size to seven members. Mr. Bate is an independent director with extensive biotechnology executive experience.
- Director Compensation: Mr. Bate received an initial option to purchase 35,000 shares at $9.38 per share, vesting over four years. He will receive a $25,000 annual fee plus meeting fees and is eligible for an annual option to purchase 15,000 shares.
- Executive Compensation (2015 Bonuses):
- Mihael Polymeropoulos (CEO): $396,000
- Paolo Baroldi (SVP, CMO): $180,000
- James Kelly (SVP, CFO): $210,000
- Executive Compensation (2016 Base Salaries and Targets):
- Mihael Polymeropoulos: $618,000 base salary; 60% target bonus.
- Paolo Baroldi: $386,000 base salary; 40% target bonus.
- James Kelly: $390,000 base salary; 40% target bonus.
- Management Changes: Gian Piero Reverberi was promoted to Senior Vice President, Acting Chief Commercial Officer, and European General Manager. Tom Gibbs, former SVP and Chief Commercial Officer, resigned to join another company and is not entitled to severance.
- Bylaw Amendments: The Board adopted the Fourth Amended and Restated Bylaws, establishing Delaware as the exclusive forum for derivative suits, breach of duty claims, and internal affairs proceedings.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary contingency noted is the resignation of the Chief Commercial Officer, which was addressed by promoting an internal candidate to the acting role.
Key Facts for Investor Verification
- Verify the impact of the Chief Commercial Officer resignation and the transition to an acting role on commercial operations.
- Review the full text of the Fourth Amended and Restated Bylaws (Exhibit 3.1) regarding the Delaware forum selection clause.
- Confirm the vesting schedule and change-of-control acceleration terms for the new director's stock options.
- Assess the total executive compensation package relative to the company's cash position and burn rate, as this filing does not provide financial context.